Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1993-02-17
2000-08-15
Fonda, Kathleen K.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514 23, 514 62, 536 552, 536 88, 5361231, 536 53, A61K 31715, A61K 31725
Patent
active
061037044
ABSTRACT:
A method of accumulating a drug and a form of hyaluronic acid in the skin and/or exposed tissue of a human includes topically administering a therapeutically effective dosage amount of a formulation which comprises at least 5 mg/cm.sup.2 of the form of hyaluronic acid and a therapeutically effective amount of the drug.
REFERENCES:
patent: 2583096 (1952-01-01), Hadidian et al.
patent: 3042667 (1962-07-01), Flodin et al.
patent: 3357784 (1967-12-01), Kasper et al.
patent: 3396081 (1968-08-01), Billek et al.
patent: 3436454 (1969-04-01), Nouvel
patent: 3792164 (1974-02-01), Bechtold et al.
patent: 3845201 (1974-10-01), Haddad et al.
patent: 3870791 (1975-03-01), Haddad et al.
patent: 3887703 (1975-06-01), Manoussos et al.
patent: 4003991 (1977-01-01), Krohn et al.
patent: 4045558 (1977-08-01), Smith et al.
patent: 4061722 (1977-12-01), Bodor et al.
patent: 4141973 (1979-02-01), Balazs
patent: 4240163 (1980-12-01), Galin
patent: 4255415 (1981-03-01), Chrai et al.
patent: 4271143 (1981-06-01), Schoenwald et al.
patent: 4272522 (1981-06-01), Balazs
patent: 4280954 (1981-07-01), Yannas et al.
patent: 4303676 (1981-12-01), Balazs
patent: 4328803 (1982-05-01), Pape
patent: 4470975 (1984-09-01), Berger et al.
patent: 4478822 (1984-10-01), Haslam et al.
patent: 4487865 (1984-12-01), Balazs et al.
patent: 4500676 (1985-02-01), Balazs
patent: 4517295 (1985-05-01), Bracke
patent: 4582865 (1986-04-01), Balazs et al.
patent: 4629623 (1986-12-01), Balazs et al.
patent: 4636524 (1987-01-01), Balazs et al.
patent: 4684627 (1987-08-01), Le Veen et al.
patent: 4686288 (1987-08-01), Lormeau et al.
patent: 4711780 (1987-12-01), Fahim
patent: 4713448 (1987-12-01), Balazs et al.
patent: 4716224 (1987-12-01), Sakurai et al.
patent: 4725585 (1988-02-01), Wenge et al.
patent: 4736024 (1988-04-01), Della Valle et al.
patent: 4746504 (1988-05-01), Nimrod et al.
patent: 4755544 (1988-07-01), Makino et al.
patent: 4782046 (1988-11-01), Brown et al.
patent: 4784990 (1988-11-01), Nimrod et al.
patent: 4784991 (1988-11-01), Nimrod et al.
patent: 4795741 (1989-01-01), Leshchiner et al.
patent: 4801619 (1989-01-01), Lindblad
patent: 4804537 (1989-02-01), Bergman et al.
patent: 4808576 (1989-02-01), Schultz et al.
patent: 4814175 (1989-03-01), Tack et al.
patent: 4814176 (1989-03-01), Makino et al.
patent: 4840941 (1989-06-01), Ueno et al.
patent: 4851521 (1989-07-01), della Valle et al.
patent: 4853224 (1989-08-01), Wong
patent: 4853226 (1989-08-01), Machida et al.
patent: 4855134 (1989-08-01), Yamahira et al.
patent: 4863907 (1989-09-01), Sakurai et al.
patent: 4877619 (1989-10-01), Richer
patent: 4879282 (1989-11-01), Saliba, Jr.
patent: 4912093 (1990-03-01), Michaeli
patent: 4913898 (1990-04-01), Altobelli et al.
patent: 4937254 (1990-06-01), Sheffield et al.
patent: 4937270 (1990-06-01), Hamilton et al.
patent: 4944941 (1990-07-01), Ammann
patent: 4957744 (1990-09-01), della Valle et al.
patent: 4963666 (1990-10-01), Malson
patent: 4965353 (1990-10-01), della Valle et al.
patent: 4970298 (1990-11-01), Silver et al.
patent: 5095037 (1992-03-01), Iwamitsu et al.
patent: 5166331 (1992-11-01), Della Valle et al.
Amsterdam A, Shemesh M, Riesel R, Amir Y, Salomon Y. Intra-ovarian inhibitor of luteinizing hormone sensitive adenylate cyclase. Israel Journal of Medical Sciences 1977; 13(9): 968-969.
Anastassiades T, Robertson W. Modulation of mitogen-dependent lymphocyte stimulation by hyaluroniccid. J Rheum. 1984; 11(6): 729-734.
Appel A, Horwitz AL, Dorfman A. Cell-free synthesis of hyaluronic acid in marfan syndrome. J. Biological Chemistry 1979; 254(23): 12199-12203.
Arzeno G, Miller D. Effect of sodium hyaluronate on corneal wound healing. Arch Ophthalmol 1982; 100: 152.
Balazs EA, Band P. Hyaluronic acid: Its structure and use. Cosmetics & Toiletries . Polymers in Cosmetics 1984; 99: 65-72.
Balazs EA, Freeman MI, et al. Hyaluronic acid and replacement of vitreous and aqueous humor. Modern Problems in Ophthalmology: Secondary Detachment of the Retina 1971; 10: 3-21.
Adams JB. Steroid hormones and breast cancer. Dissertation Abstracts International 1981; 42(4): 1425B.
Ahlgren T, Jarstrand C. Hyaluronic acid enhances phagocytosis of human monocytes in vitro. J Clinical Immunology 1984; 4(3): 246-249.
Alaverdyan MI, Ter-Avetisyan AT. Effect of hyaluronidase, hyaluronic acid, and some other substances on postradiational experimental bacteriemai. Bulletin of Experimental Biology and Medicine 1967; 64(9): 967-969.
Alexander P. Ageing skin: Remedial measures. Manuf. Chemist 1985; Oct.: 35, 37, 39.
Altman RD, Kapila P, Dean DD, Howell DS. Future therapeutic trends in osteoarthritis. Scand. J. Rheumatology 1989; Suppl. 77: 37-42.
Abatangelo G, Martelli M, Vecchia P. Healing of hyaluronic acid-enriched wounds: Histological observations. J. Surgical Research 1983; 35: 410-416.
Abatangelo G, Corvito R, et al. Cell detachment mediated by hyaluronic acid. Exp. Cell Res. 1982; 137: 73-78.
Balazs EA, Gibbs DA. The rheological properties and biological function of hyaluronic acid. In: Chemistry and Molecular Biology of the Intercellullar Matrix. vols. III. New York: Academic Press, 1970. pp. 1241-1253.
Barondes SH. Bifunctional properties of lectins: Lectins redefined. TIBS 1988; 13 (Dec.): 480-482.
Barron BA, et al. Comparison of the effects of viscoat and healon on postoperative intraocular pressure. Am. J. Ophthallmology 1985; 100: 377-384.
Biggar WD, Sturgess JM. Role of lysozyme in the microbicidal activity of rat alveolar macrophages. Infection and Immunity 1977; 16(3): 974-982.
Binkhorst CD. Advantages and disadvantages of intracamerular Na-Hyaluronate (Healon) in intraocular lens surgery. Documenta Ophthalmologica 1981; 50: 233-235.
Blumenkrantz, N, Asboe-Hansen G. Reaction of cationic groups of chlorpromazine with anionic macromolecules: Complexes with DNA, RNA, hyaluronic acid and heparin. Acta Pharmacol. et Toxiicol. 1974; 34: 27-32.
Bowen BR, Nguyen T, Lasky LA. Characterization of a human homologue of the murine peripheral lymph node homing receptor. J Cell Biology 1989; 109(Jul.): 421-427.
Boyce ST, Christianson DJ, Hansbrough JF. Structure of a collagen-GAG dermal skin substitute optimized for cultured human epidermal keratinocytes. J. Biomedical Material Research 1988; 22: 939-957.
Brandstetter W, Kiesewetter E, Wohlzogen FX. Influencing experimental pathological changes i rodents with hyaluronic acid. [Translation of : Beeinflussung experimentell-pathologischer veranderungen bei nagern durch hyaluronsaure.] Archive for Experimental Pathology and Pharmacology / Archiv Fur Experimentelle Pathologie 1957; 231(2): 186-198.
Brandt K. Modification of chemotaxis by synovial fluid hyaluronate. Arthritis and Rheumatism 1970; 13(3): 308-309.
Brown TA, Bouchard T, St. John T, Wayner E, Carter WG. Human keratinocytes express a new CD44 core protein (CD44E) as a heparan-sulfate intrinsic membrane proteoglycan with additional exons. J Cell Biology 1991; 113(1): 207-221.
Bruno RN. Osservazioni sull'impiego comparativo di sale sodico dell'acido ialuronico e dell'estratto di Triticum vulgaris in 20 casi di soggetti affetti da ulcere a deversa etiologia. [Summary in English] Il Policlinico. Sezione Medica: 1983; 90(4): 340-344.
Burk DT. Morphological effects of streptomyces hyaluronidase treatment on the ouitgrowht of the nasal processes in mouse embryos. J Craniofacial Genetics 1985; 5: 385-398.
Camber O, Edman P, Gurny R. Influence of sodium hyaluronate on the meiotic effect of pilocarpine in rabbits. Current Eye Research 1987; 6(6): 779-784.
U.S. application No. 07/338,106, Falk, filed Apr. 4, 1989.
Camber O, Lundgren P. Diffusion of some low molecular weight compounds in sodium hyaluronate. Acta Pharmaceutica Suecica 1985; 22(6): 315-320.
Carbonetto S, Gruver MM, Turner DC. Nerve Fiber grwoth in culture on fibronectin, collagen, and glycosaminoglycan substrates. J. Neuroscience 1983; 3(11): 2324-2335.
Chang N-S. Hyaluronic acid and complement interactions. Dissertation Abstracts International 1985; 45(12): 3766-B.
Chang S-C. Pro-drug and vehicle approaches to improve the therapeutic index of topically applied timolol in the p
Asculai Samuel Simon
Falk Rudolf Edgar
Harper David William
Hochman David
Klein Ehud Shmuel
Fonda Kathleen K.
Hughes Ivor M.
Hughes Neil H.
Hyal Pharmaceutical Corporation
Sarkis Marcelo K.
LandOfFree
Therapeutic methods using hyaluronic acid does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic methods using hyaluronic acid, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic methods using hyaluronic acid will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2006941